Opaleye Management Inc. Protagonist Therapeutics, Inc Transaction History
Opaleye Management Inc.
- $390 Million
- Q2 2024
A detailed history of Opaleye Management Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Opaleye Management Inc. holds 105,000 shares of PTGX stock, worth $4.93 Million. This represents 0.93% of its overall portfolio holdings.
Number of Shares
105,000
Previous 112,700
6.83%
Holding current value
$4.93 Million
Previous $3.26 Million
11.6%
% of portfolio
0.93%
Previous 0.79%
Shares
8 transactions
Others Institutions Holding PTGX
# of Institutions
204Shares Held
58.8MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$274 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$271 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$248 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$156 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$152 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.31B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...